The efficacy of azvudine in treating hospitalized COVID-19 patients: a retrospective single-center cohort analysis.

ABSTRACT:

Background

Although coronavirus disease 2019 (COVID-19) is no longer classified as a Public Health Emergency of International Concern (PHEIC), the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to undergo genetic mutations, leading to persistent public health challenges. It is still necessary to evaluate the effectiveness and safety of existing clinical drug treatments. In this study, we mainly evaluate the treatment effect of azvudine in the real world of hospitalized COVID-19 patients.

Methods

This retrospective cohort analysis included hospitalized patients diagnosed with COVID-19 from December 1, 2022, to October 31, 2023. Patients receiving azvudine were categorized as the treatment group, while those without antiviral therapy constituted the con

SUBMITTER: Lei H 

PROVIDER: S-EPMC12603486 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature